Guideline‑Recommended Pharmacologic Management of Apathy in Dementia

1. Current Guideline Positions

2. Established Pharmacologic Options

2.1 Cholinesterase Inhibitors

2.2 Memantine

2.3 SSRIs (including potential off‑label use of vortioxetine)

2.4 Stimulant Medications for Isolated Apathy

3. Evidence Gaps Specific to Vortioxetine

4. Non‑Pharmacologic Prioritization

Dementia Treatment Guidelines

Pharmacological Interventions

• The American College of Physicians recommends cholinesterase inhibitors (donepezil, galantamine, rivastigmine) for mild to moderate dementia, particularly Alzheimer's disease, as they show statistically significant but clinically marginal improvements in cognition and global function 4, 5
• Memantine is recommended for moderate to severe dementia, with treatment decisions based on tolerability, adverse effect profile, ease of use, and cost 4, 5
• Most studies of approved medications are short-duration (6 months), limiting ability to detect long-term benefits, and effects on behavior and quality of life are less consistently demonstrated than effects on cognition 6, 7

Non-Pharmacological Interventions

• Non-pharmacological approaches should take precedence over medications for behavioral and psychological symptoms of dementia, and cognitive training, physical exercise, and dietary interventions may have positive impacts 5

Limitations of Current Treatments

• Clinical improvements from approved medications are often modest despite statistical significance, and the evidence for their long-term benefits is limited 8, 9